Wedge Capital Management L L P NC Raises Stock Position in Bristol Myers Squibb Company $BMY

Wedge Capital Management L L P NC lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 528,057 shares of the biopharmaceutical company’s stock after acquiring an additional 35,072 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Bristol Myers Squibb were worth $30,427,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Bristol Myers Squibb by 59.4% in the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares during the period. United Bank grew its holdings in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after purchasing an additional 3,277 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $221,000. Finally, Nebula Research & Development LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at approximately $405,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst earnings estimates increased: Erste Group Bank raised its FY2026 EPS forecast for BMY to $6.96 from $6.34, matching the broader consensus, and lifted its FY2027 estimate to $6.51 from $6.10. The revisions suggest improving confidence in the company’s earnings outlook. Bristol Myers Squibb earnings estimate revisions
• Positive Sentiment: $2.3 billion Houston manufacturing campus: BMY plans to build an approximately 600,000-square-foot advanced manufacturing and life sciences facility at Generation Park in Houston. The project is expected to create about 500 permanent jobs and roughly 2,000 construction jobs, expanding the company’s U.S. production capacity and supporting its previously announced $40 billion domestic investment commitment. Bristol Myers to build $2.3 billion manufacturing site in Houston
• Neutral Sentiment: Broker sentiment remains favorable but not strongly bullish: BMY continues to carry an average “Moderate Buy” recommendation. Recent commentary highlights the company’s growth portfolio and pipeline, but also cautions that generic competition and the stock’s prior gains could limit near-term upside. Bristol Myers Squibb receives Moderate Buy recommendation
• Negative Sentiment: Merger speculation is unconfirmed: Reports that BMY held merger discussions with AstraZeneca helped send AZN sharply lower, but neither company confirmed the talks. The lack of confirmation and skepticism from Wall Street may weigh on BMY by raising questions about deal costs, integration risks and strategic priorities, even though a combination would create one of the world’s largest drugmakers. AstraZeneca versus Bristol Myers Squibb merger speculation

Bristol Myers Squibb Price Performance

Shares of BMY opened at $63.66 on Wednesday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.10. The stock’s fifty day moving average is $59.09 and its 200-day moving average is $58.80. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The firm has a market capitalization of $130.05 billion, a price-to-earnings ratio of 14.02, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.96 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BMY. Truist Financial reaffirmed a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Cantor Fitzgerald restated a “neutral” rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, Roth Capital started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.